Literature DB >> 15213150

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Frances Bowe1, Ed C Lavelle, Edel A McNeela, Christine Hale, Simon Clare, Beatrice Arico, Marzia M Giuliani, Aaron Rae, Alan Huett, Rino Rappuoli, Gordon Dougan, Kingston H G Mills.   

Abstract

Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, which is still a major cause of meningitis. We evaluated the immunogenicity of three surface-exposed proteins from serogroup B Neisseria meningitidis (App, NhhA, and NadA) identified during whole-genome sequencing. Mice were immunized intranasally with individual proteins in the presence of wild-type Escherichia coli heat-labile enterotoxin (LTwt), LTR72, a partially inactivated mutant, or LTK63, a completely nontoxic mutant, as the adjuvant. Each of the meningococcal proteins induced significant cellular responses; NhhA and NadA induced strong antibody responses, but only NadA induced bactericidal antibody when administered intranasally with mucosal adjuvants. In addition, immunoglobulin A and bactericidal antibodies were detected in the respiratory tract following intranasal delivery of NadA. Analysis of antigen-specific cytokine production by T cells from immunized mice revealed that intranasal immunization with NadA alone failed to generate detectable cellular immune responses. In contrast, LTK63, LTR72, and LTwt significantly augmented NadA-specific gamma interferon, interleukin-4 (IL-4), IL-5, and IL-10 production by spleen and lymph node cells, suggesting that both Th1 and Th2 cells were induced in vivo. The strongest cellular responses and highest bactericidal antibody titers were generated with LTR72 as the adjuvant. These findings demonstrate that the quality and magnitude of the immune responses generated by mucosal vaccines are influenced by the antigen as well as the adjuvant and suggest that nasal delivery of NadA with mucosal adjuvants has considerable potential in the development of a mucosal vaccine against serogroup B meningococci.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213150      PMCID: PMC427466          DOI: 10.1128/IAI.72.7.4052-4060.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  A common conserved amino acid motif module shared by bacterial and intercellular adhesins: bacterial adherence mimicking cell cell recognition?

Authors:  Maria Scarselli; Rino Rappuoli; Vincenzo Scarlato
Journal:  Microbiology (Reading)       Date:  2001-02       Impact factor: 2.777

2.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Authors:  M E Ramsay; N Andrews; E B Kaczmarski; E Miller
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

3.  Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.

Authors:  F W van Ginkel; R J Jackson; Y Yuki; J R McGhee
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

4.  Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000.

Authors:  K Cartwright; N Noah; H Peltola
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

5.  Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.

Authors:  H Tettelin; N J Saunders; J Heidelberg; A C Jeffries; K E Nelson; J A Eisen; K A Ketchum; D W Hood; J F Peden; R J Dodson; W C Nelson; M L Gwinn; R DeBoy; J D Peterson; E K Hickey; D H Haft; S L Salzberg; O White; R D Fleischmann; B A Dougherty; T Mason; A Ciecko; D S Parksey; E Blair; H Cittone; E B Clark; M D Cotton; T R Utterback; H Khouri; H Qin; J Vamathevan; J Gill; V Scarlato; V Masignani; M Pizza; G Grandi; L Sun; H O Smith; C M Fraser; E R Moxon; R Rappuoli; J C Venter
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

6.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Authors:  M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

7.  Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis.

Authors:  H A Hadi; K G Wooldridge; K Robinson; D A Ala'Aldeen
Journal:  Mol Microbiol       Date:  2001-08       Impact factor: 3.501

8.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 9.  Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

Authors:  M Pizza; M M Giuliani; M R Fontana; E Monaci; G Douce; G Dougan; K H Mills; R Rappuoli; G Del Giudice
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

10.  Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.

Authors:  E J Ryan; E McNeela; M Pizza; R Rappuoli; L O'Neill; K H Mills
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

View more
  15 in total

1.  Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis.

Authors:  D P J Turner; A G Marietou; L Johnston; K K L Ho; A J Rogers; K G Wooldridge; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Virulence determinants involved in differential host niche adaptation of Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Stephanie Schielke; Matthias Frosch; Oliver Kurzai
Journal:  Med Microbiol Immunol       Date:  2010-04-09       Impact factor: 3.402

3.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

4.  Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.

Authors:  Zhiming Huo; Ruchi Sinha; Edel A McNeela; Ray Borrow; Rafaela Giemza; Catherine Cosgrove; Paul T Heath; Kingston H G Mills; Rino Rappuoli; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

6.  Microsatellite instability regulates transcription factor binding and gene expression.

Authors:  Patricia Martin; Katherine Makepeace; Stuart A Hill; Derek W Hood; E Richard Moxon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

7.  Phage display revisited: Epitope mapping of a monoclonal antibody directed against Neisseria meningitidis adhesin A using the PROFILER technology.

Authors:  Veronica Lanza Cariccio; Maria Domina; Salvatore Benfatto; Mario Venza; Isabella Venza; Agnese Faleri; Marco Bruttini; Erika Bartolini; Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Nathalie Norais; Erica Borgogni; Angelina Midiri; Roberta Galbo; Letizia Romeo; Carmelo Biondo; Vega Masignani; Giuseppe Teti; Franco Felici; Concetta Beninati
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

Review 8.  B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

9.  IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone.

Authors:  Johannes Elias; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

10.  Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Berhanu Melak; Degu Berhanu; Morten Harboe; Jan Kolberg; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2008-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.